



FEP Medical Policy Manual

FEP 2.04.103 Genetic Testing for Macular Degeneration

Effective Policy Date: July 1, 2023

Original Policy Date: June 2015

Related Policies:

None

Genetic Testing for Macular Degeneration

Description

Description

Age-related macular degeneration is a complex disease involving both genetic and environmental influences. Testing for variants at certain genetic loci has been proposed to predict the risk of developing advanced age-related macular degeneration. Age-related macular degeneration is divided into the dry form, associated with slowly progressive vision loss, and the wet form, which may be associated with rapidly progressive and severe vision loss. The risks of age-related macular degeneration and of developing the wet form are associated with genetic and nongenetic (eg, age, smoking) factors.

OBJECTIVE

The objective of this evidence review is to determine whether use of genetic testing improves the net health outcome in patients with suspected age-related macular degeneration or disease progression in those with age-related macular degeneration.

POLICY STATEMENT

Genetic testing for macular degeneration is considered **investigational**.

POLICY GUIDELINES

Genetics Nomenclature Update

The Human Genome Variation Society nomenclature is used to report information on variants found in DNA and serves as an international standard in DNA diagnostics. It was implemented for genetic testing medical evidence review updates starting in 2017 (see Table PG1). The Society's nomenclature is recommended by the Human Variome Project, the Human Genome Organization, and by the Human Genome Variation Society itself.

The American College of Medical Genetics and Genomics and the Association for Molecular Pathology standards and guidelines for interpretation of sequence variants represent expert opinion from both organizations, in addition to the College of American Pathologists. These recommendations primarily apply to genetic tests used in clinical laboratories, including genotyping, single genes, panels, exomes, and genomes. Table PG2 shows the recommended standard terminology <97>"pathogenic," "likely pathogenic," "uncertain significance," "likely benign," and "benign" <97>to describe variants identified that cause Mendelian disorders.

Table PG1. Nomenclature to Report on Variants Found in DNA

Previous	Updated	Definition
Mutation	Disease-associated variant	Disease-associated change in the DNA sequence
	Variant	Change in the DNA sequence
	Familial variant	Disease-associated variant identified in a proband for use in subsequent targeted genetic testing in first-degree relatives

Table PG2. ACMG-AMP Standards and Guidelines for Variant Classification

Variant Classification	Definition
Pathogenic	Disease-causing change in the DNA sequence
Likely pathogenic	Likely disease-causing change in the DNA sequence
Variant of uncertain significance	Change in DNA sequence with uncertain effects on disease
Likely benign	Likely benign change in the DNA sequence
Benign	Benign change in the DNA sequence

ACMG: American College of Medical Genetics and Genomics; AMP: Association for Molecular Pathology.

Genetic Counseling

Genetic counseling is primarily aimed at patients who are at risk for inherited disorders, and experts recommend formal genetic counseling in most cases when genetic testing for an inherited condition is considered. The interpretation of the results of genetic tests and the understanding of risk factors can be very difficult and complex. Therefore, genetic counseling will assist individuals in understanding the possible benefits and harms of genetic testing, including the possible impact of the information on the individual's family. Genetic counseling may alter the utilization of genetic testing substantially and may reduce inappropriate testing. Genetic counseling should be performed by an individual with experience and expertise in genetic medicine and genetic testing methods.

BENEFIT APPLICATION

Experimental or investigational procedures, treatments, drugs, or devices are not covered (See General Exclusion Section of brochure).

Screening (other than the preventive services listed in the brochure) is not covered. Please see Section 6 General exclusions.

Benefits are available for specialized diagnostic genetic testing when it is medically necessary to diagnose and/or manage a patient's existing medical condition. Benefits are not provided for genetic panels when some or all of the tests included in the panel are not covered, are experimental or investigational, or are not medically necessary.

FDA REGULATORY STATUS

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments (CLIA). Laboratories that offer laboratory-developed tests must be licensed by the CLIA for high-complexity testing. To date, the U.S. Food and Drug Administration has chosen not to require any regulatory review of this test.

RATIONALE

Summary of Evidence

For individuals who are asymptomatic with risk of developing age-related macular degeneration who receive genetic testing for age-related macular degeneration, the evidence includes genetic association studies and risk-prediction models. Relevant outcomes are test accuracy, change in disease status, and functional outcomes. The clinical validity of genetic testing appears to provide a small, incremental benefit to risk stratification based on nongenetic risk factors. The clinical utility of genetic testing for age-related macular degeneration is limited, in that there are currently no preventive measures that can be undertaken. No studies have shown improvements in health outcomes in patients identified as being at high-risk based on genetic testing. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with age-related macular degeneration who receive genetic testing for age-related macular degeneration, the evidence includes genetic association studies and risk-prediction models. Relevant outcomes are test accuracy, change in disease status, and functional outcomes. The clinical utility of genetic testing in patients who have age-related macular degeneration is limited, in that genetic testing has not been shown to be superior to clinical evaluation in determining the risk of progression of disease. In addition, there is no known association with specific genotypes and specific therapies. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

SUPPLEMENTAL INFORMATION

Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

American Academy of Ophthalmology

The 2014 American Academy of Ophthalmology (AAO) recommendations specific to genetic testing for complex eye disorders like age-related macular degeneration have indicated that the presence of any 1 of the disease-associated variants is not highly predictive of disease development.²¹ The AAO found that, in many cases, standard clinical diagnostic methods like biomicroscopy, ophthalmoscopy, tonography, and perimetry would be more accurate for assessing a patient's risk of vision loss from a complex disease than the assessment of a small number of genetic loci. The AAO concluded that genetic testing for complex diseases will become relevant to the routine practice of medicine when clinical trials demonstrate that patients with specific genotypes benefit from specific types of therapy or surveillance; until such benefit can be demonstrated, routine genetic testing of patients with complex eye diseases, or unaffected patients with a family history of such diseases, is not warranted.

In 2019, AAO published a Preferred Practice Pattern on age-related macular degeneration, which noted that the routine use of genetic testing is not recommended at this time due to lack of prospective clinical evidence.²²

American Society of Retina Specialists

In 2017, the American Society of Retina Specialists published special correspondence on the use of genetic testing in the management of patients with age-related macular degeneration.²³ The Society concluded that:

- While age-related macular degeneration genetic testing may provide information on progression from intermediate to advanced age-related macular degeneration, there is no clinical evidence that altering management of patients with genetically higher risk for progression results in better visual outcomes compared with patients with genetically lower risk for progression.
- Age-related macular degeneration genetic testing in patients with neovascular age-related macular degeneration does not provide clinically relevant information regarding response to anti-vascular endothelial growth factor treatment and is therefore not recommended for this population.
- Currently, there is insufficient evidence to support the use of genetic testing in patients with age-related macular degeneration in regard to nutritional supplement recommendations.

U.S. Preventive Services Task Force Recommendations

Not applicable.

Medicare National Coverage

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

REFERENCES

1. Centers for Disease Control and Prevention (CDC). Prevalence of Age-Related Macular Degeneration (AMD). Updated October 31, 2022. <https://www.cdc.gov/visionhealth/vehss/estimates/amd-prevalence.html#:~:text=Overall%20Findings&text=Prevalence%20of%20AMD%20increased%20with,among%20people%20aged%20%E2%89%A585>. Accessed January 30, 2023.
2. Colijn JM, Meester-Smoor M, Verzijden T, et al. Genetic Risk, Lifestyle, and Age-Related Macular Degeneration in Europe: The EYE-RISK Consortium. *Ophthalmology*. Jul 2021; 128(7): 1039-1049. PMID 33253757
3. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. *Arch Ophthalmol*. Oct 2001; 119(10): 1417-36. PMID 11594942
4. Gorin MB. Genetic insights into age-related macular degeneration: controversies addressing risk, causality, and therapeutics. *Mol Aspects Med*. Aug 2012; 33(4): 467-86. PMID 22561651
5. Lim LS, Mitchell P, Seddon JM, et al. Age-related macular degeneration. *Lancet*. May 05 2012; 379(9827): 1728-38. PMID 22559899
6. Kim IK. Genetic testing for AMD inches forward. 2012; <https://www.reviewofophthalmology.com/article/genetic-testing-for-amd-inches-forward>. Accessed January 30, 2023.
7. Hageman GS, Gehrs K, Lejnine S, et al. Clinical validation of a genetic model to estimate the risk of developing choroidal neovascular age-related macular degeneration. *Hum Genomics*. Jul 2011; 5(5): 420-40. PMID 21807600
8. Jakobsdottir J, Gorin MB, Conley YP, et al. Interpretation of genetic association studies: markers with replicated highly significant odds ratios may be poor classifiers. *PLoS Genet*. Feb 2009; 5(2): e1000337. PMID 19197355
9. Seddon JM, Reynolds R, Maller J, et al. Prediction model for prevalence and incidence of advanced age-related macular degeneration based on genetic, demographic, and environmental variables. *Invest Ophthalmol Vis Sci*. May 2009; 50(5): 2044-53. PMID 19117936
10. Seddon JM, Silver RE, Kwong M, et al. Risk Prediction for Progression of Macular Degeneration: 10 Common and Rare Genetic Variants, Demographic, Environmental, and Macular Covariates. *Invest Ophthalmol Vis Sci*. Apr 2015; 56(4): 2192-202. PMID 25655794
11. Klein ML, Francis PJ, Ferris FL, et al. Risk assessment model for development of advanced age-related macular degeneration. *Arch Ophthalmol*. Dec 2011; 129(12): 1543-50. PMID 21825180
12. Govindaiah A, Baten A, Smith RT, et al. Optimized Prediction Models from Fundus Imaging and Genetics for Late Age-Related Macular Degeneration. *J Pers Med*. Nov 01 2021; 11(11). PMID 34834479
13. Ajana S, Cougnard-Groire A, Colijn JM, et al. Predicting Progression to Advanced Age-Related Macular Degeneration from Clinical, Genetic, and Lifestyle Factors Using Machine Learning. *Ophthalmology*. Apr 2021; 128(4): 587-597. PMID 32890546
14. de Breuk A, Acar IE, Kersten E, et al. Development of a Genotype Assay for Age-Related Macular Degeneration: The EYE-RISK Consortium. *Ophthalmology*. Nov 2021; 128(11): 1604-1617. PMID 32717343

15. Fauser S, Lambrou GN. Genetic predictive biomarkers of anti-VEGF treatment response in patients with neovascular age-related macular degeneration. *Surv Ophthalmol*. 2015; 60(2): 138-52. PMID 25596882
16. Chew EY, Klein ML, Clemons TE, et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. *Ophthalmology*. Nov 2014; 121(11): 2173-80. PMID 24974817
17. Hagstrom SA, Ying GS, Maguire MG, et al. VEGFR2 Gene Polymorphisms and Response to Anti-Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration. *Ophthalmology*. Aug 2015; 122(8): 1563-8. PMID 26028346
18. Hagstrom SA, Ying GS, Pauer GJ, et al. VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT). *JAMA Ophthalmol*. May 2014; 132(5): 521-7. PMID 24652518
19. Awh CC, Lane AM, Hawken S, et al. CFH and ARMS2 genetic polymorphisms predict response to antioxidants and zinc in patients with age-related macular degeneration. *Ophthalmology*. Nov 2013; 120(11): 2317-23. PMID 23972322
20. Balikova I, Postelmans L, Pasteels B, et al. Genetic biomarkers in the VEGF pathway predicting response to anti-VEGF therapy in age-related macular degeneration. *BMJ Open Ophthalmol*. 2019; 4(1): e000273. PMID 31909188
21. Stone EM, Aldave AJ, Drack AV, et al. Recommendations of the American Academy of Ophthalmology Task Force on Genetic Testing. 2014; <https://www.aao.org/clinical-statement/recommendations-genetic-testing-of-inherited-eye-d>. Accessed January 30, 2023.
22. Flaxel CJ, Adelman RA, Vemulakonda GA, et al; American Academy of Ophthalmology Preferred Practice Pattern (PPP) Retina/Vitreous Committee. Age-Related Macular Degeneration PPP. 2019; <https://www.aao.org/preferred-practice-pattern/age-related-macular-degeneration-ppp>. Accessed January 30, 2023.
23. Csaky KG SA, Kaiser PK, et al. The Use of Genetic Testing in the Management of Patients with Age-Related Macular Degeneration: American Society of Retina Specialists Genetics Task Force Special Report. 2017; <https://www.asrs.org/content/documents/articleasrstaskforcereportjvrd117.pdf>. Accessed January 30, 2023.

POLICY HISTORY - THIS POLICY WAS APPROVED BY THE FEP® PHARMACY AND MEDICAL POLICY COMMITTEE ACCORDING TO THE HISTORY BELOW:

Date	Action	Description
June 2015	New policy	
September 2016	Replace policy	Policy updated with literature review, references 9 and 11-13 added. Policy statement unchanged.
March 2017	Replace policy	Policy updated with literature review through January 25, 2017; no references added. ARUP test reference removed. The policy is revised with updated genetics nomenclature. Policy statement unchanged.
June 2018	Replace policy	Policy updated with literature review through January 8, 2018; reference 16 was added. Policy statement unchanged. Summary of Evidence edited to reflect Benefit Application information of "existing medical condition,."
June 2019	Replace policy	Policy updated with literature review through January 9, 2019; no references added. Policy statement unchanged.
June 2020	Replace policy	Policy updated with literature review through January 13, 2020; no references added. Policy statement unchanged.
June 2021	Replace policy	Policy updated with literature review through January 20, 2021; reference added. Policy statement unchanged.
June 2022	Replace policy	Policy updated with literature review through January 14, 2022; references added. Policy statement unchanged.
June 2023	Replace policy	Policy updated with literature review through January 30, 2023; reference added. Policy statement unchanged.

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.